Cabozantinib improves progression-free survival in metastatic renal cell carcinoma
Tuesday, October 11, 2016 - 04:31
in Health & Medicine
Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research.